" It is hard to see this as anything but a conflict of interest and an abuse of position," Mr. Wyden said. In particular, Mr. Wyden pressed Mr. Price over his investments in Innate Immunotherapeutics, which the senator said could be affected by legislation that comes before Congress. Mr. Price said he had done nothing wrong. 